US 11058757

US patent 11058757, titled "Saccharide-polypeptide conjugate compositions and methods of use thereof," was granted to Pogona LLC. The inventors are Bruce D. Forrest and Jack D. Love. The patent was filed on March 31, 2017, and issued on July 13, 2021.

Abstract:
The patent describes saccharide-polypeptide conjugate compositions, specifically vaccine compositions, which consist of a saccharide antigen linked to a polypeptide carrier. These compositions and methods are intended to generate an immune response in a subject against Streptococcus pneumoniae, targeting either a single serotype or a combination of different serotypes of the bacteria.

Independent Claims Overview:

• Claim 1: This claim protects a pharmaceutical composition that acts as a multi-component vaccine. It specifies a mixture of at least five distinct conjugate components. Each component consists of a saccharide from a unique Streptococcus pneumoniae serotype (e.g., Serotype 1 saccharide, Serotype 2 saccharide, etc.) that is chemically attached to a polypeptide carrier. A crucial aspect is that the five Streptococcus pneumoniae serotypes must be different from each other, and the saccharides themselves are not derived from the polypeptide carrier.
• Claim 15: This claim covers a method of treatment using the composition described in Claim 1. It details a process for stimulating an immune response in a subject (e.g., a human or animal) against Streptococcus pneumoniae by administering the pharmaceutical composition of Claim 1 to that subject.
• Claim 16: This claim outlines a manufacturing method for the pharmaceutical composition. It involves a process of combining at least five separate conjugate components, where each component features a saccharide from a different Streptococcus pneumoniae serotype covalently linked to a polypeptide. As with Claim 1, the five Streptococcus pneumoniae serotypes must be distinct, and the saccharides are not derived from the polypeptide.

CAFC 2026 Dockets:
As of April 26, 2026, the provided information indicates that two PTAB (Patent Trial and Appeal Board) cases (IPR2026-00221 and IPR2026-00189) have been filed against this patent and are currently pending. Additionally, a U.S. District Court case (2:25-cv-15294) was filed in the New Jersey District Court. However, there is no authoritative information explicitly stating that any appeals related to US11058757 have reached the Court of Appeals for the Federal Circuit (CAFC) dockets in 2026. Appeals to CAFC typically follow final decisions from the PTAB or district courts, and given the pending status of the IPRs and the relatively recent filing of the district court case, a CAFC docket for 2026 related to these specific proceedings is not yet confirmed.